Exelixis (EXEL) Tops Q3 EPS by 13c, Tops on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Exelixis (EXEL) PT Raised to $29 at Stephens
October 30, 2024 6:27 AM EDTStephens analyst Sudan Loganathan raised the price target on Exelixis (NASDAQ: EXEL) to $29.00 (from $23.00) while maintaining a Equal Weight rating.
The analyst comments "EXEL reported 3Q24 financial results yesterday (10/29/2024) after market close and provided regulatory and business updates. Key highlights on the... More
Exelixis (EXEL) PT Raised to $38 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Exelixis (NASDAQ: EXEL) to $38.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Exelixis reported 3Q24 financial results, beating consensus on top-line revenue and GAAP EPS due to continued strength of cabozantinib. Total... More
